Your search history is turned on.
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario
XORTX Therapeutics Inc. 3710 33rd Street NW, Calgary, Alberta, Canada T2L 2M1 T + 1 403 455 7717 | xortx.com | TSXV | NASDAQ : XRTX I Frankfurt Borse : ANU XORTX Reprices Warrants Issued in Connection with Previous Private Placements CALGARY, AB April 30, 2024 XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRT...
Date: April 22, 2024 Jurisdictions: Alberta, British Columbia, Ontario
XORTX Therapeutics Inc. 3710 33rd Street NW, Calgary, Alberta, Canada T2L 2M1 T + 1 403 455 7717 | xortx.com | TSXV | NASDAQ : XRTX I Frankfurt Borse : ANU XORTX Announces Publication of Key Research in ADPKD CALGARY, AB April 22, 2024 XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Fran...
Date: April 8, 2024 Jurisdictions: Alberta, British Columbia, Ontario
XORTX Therapeutics Inc. 3710 33rd Street NW, Calgary, Alberta, Canada T2L 2M1 T + 1 403 455 7717 | xortx.com | TSXV | NASDAQ : XRTX I Frankfurt Borse : ANU XORTX Welcomes New Member to the Board of Directors CALGARY, AB April 8, 2024 XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt...
XORTX Therapeutics Inc. 3710 33rd Street NW, Calgary, Alberta, Canada T2L 2M1 T + 1 403 455 7717 | xortx.com | TSXV | NASDAQ : XRTX I Frankfurt Borse : ANU XORTX Announces Participation in Spring 2024 Investor Conferences CALGARY, AB April 8, 2024 XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSX...
Date: April 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Rules and Policies FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, James Fairbairn, the Chief Financial Officer of XORTX Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information tha...
Rules and Policies FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Allen Davidoff, the Chief Executive Officer of XORTX Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that a...
XORTX THERAPEUTICS INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 APRIL 2, 2024 i TABLE OF CONTENTS Page REFERENCE INFORMATION .................................................................................................
1 XORTX THERAPEUTICS INC. Management Discussion and Analysis For the year ended December 31, 2023 This management discussion and analysis of financial position and results of operations (MD&A) is prepared as at April 2, 2024 and should be read in conjunction with the audited consolidated financial statements and related notes thereto ...
Date: April 2, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, FAIRBAIRN, James, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasona...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...